Materials and Methods

Mice.
C57BL/6 (WT), $\text{Rag}1^{-/-}$, $\text{Rag}2^{-/-}\text{gc}^{-/-}$, $\text{IL}-13^{-/-}$ and C57BL/6 germ-free mice were purchased from Taconic Farms. All mice were bred and maintained under pathogen-free conditions at an American Association for the Accreditation of Laboratory Animal Care accredited animal facility at the NIAID and housed in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals under an animal study proposal approved by the NIAID Animal Care and Use Committee. All mice were used between 6 and 13 weeks of age.

Generation of RARα$^{fl/fl}$ mice.
RARα$^{fl/fl}$ mice were generated using a similar targeting strategy previously described$^{35}$. In brief the targeting vector was generated using BAC clones from the C57BL/6J RPCI-23 BAC library carrying exon 3 of the RARA gene flanked by LoxP sites. The construct was transfected into TaconicArtemis C57BL/6N Tac ES cell line. Correctly targeted ES cells were injected into Balb/c blastocysts to screen for chimerism. Chimeric mice where bred to C57BL/6 females and subsequent to Flp-deleter mice to remove positive selection markers.

Diet Studies.
Vitamin A-deficient (TD.10991) and -sufficient (20,000 IU vitamin A/kg, TD.10992) diets were purchased from Harlan Teklad Diets. At day 14.5 of gestation, pregnant females were administered either vitamin A-deficient or -sufficient diet and maintained on diet until weaning of litter. Weanlings were maintained on special diet throughout study.
**Cell isolation from the lamina propria and Flow Cytometry.**

Cells from small and large intestinal lamina propria (Lp) were prepared as previously described. Single-cell suspensions were stained with CD16/32 (eBioscience) and with fluorochrome-conjugated antibodies against any combination of the following surface antigens: CD4, CD8α, CD11b, CD11c, DX5, CD49b, TCR-β, TCR-γδ, CD19, Ter119, NK1.1, Gr-1 and Thy1.2. Prior to fixation Live/Dead Fixable Blue Cell Stain Kit (Invitrogen) was used to exclude dead cells. For examination of transcription factors and cellular proliferation, cells were subsequently treated with the FOXP3 staining kit (eBioscience) in accordance with the manufacturer's instructions and stained for 20 min at room temperature with fluorochrome-conjugated antibodies against the following: RORgt, GATA3 and Ki67. (Clone numbers are listed in table S1 and gating strategies are supplied in Fig. S22)

**Intracellular cytokine staining.**

Isolated cells from lamina propria were stimulated for 2 h with phorbol 12-myristate 13-acetate (PMA) (50ng/ml) and ionomycin (2.5µg/ml) in the presence of Brefeldin A (1µg/ml) (GolgiPlug, BD Biosciences).

**Cell isolation from the lung and skin.**

Tissues were diced followed by digestion with 0.25mg/ml liberase TL (Roche) at 37°C for 45 min (lung) or liberase and 1mg/ml DNase at 37°C for 1h 15min (skin). Isolated lung cells were further purified using a 37.5% Percoll gradient followed by lysis of red blood cells with ACK.

**Fluorescence-activated cell sorting and in vitro culture of ILC and ILC2P.**

ILC3 were sorted by flow cytometry from small intestine Lp cells from WT and VAI mice based on the absence of lineage markers (CD4, CD8α, CD11b, CD11c, DX5, CD49b, TCR-β, TCR-γδ, CD19, Ter119, NK1.1 and Gr-1) but expression of
Thy1.2 and IL-7R. ILC2 were sorted as lineage negative, Thy1.2\(^+\), KLRG1\(^+\). ILC2 progenitors (ILC2P) were sorted from the bone marrow of Rag1\(^{-/-}\) mice by the absence of lineage makers and c-Kit, but expression of IL-7R, CD25 and high levels of Sca-1\(^{37-39}\). RPMI 1640 supplemented with 10% FBS, penicillin, streptomycin, HEPES, glutamine, nonessential amino acids, and 50 mM of β-mercaptoethanol (Complete Media) was used for in vitro culture. ILC2 (5x10\(^3\) cells), ILC3 (10x10\(^3\) cells) or ILC2P (2.4x10\(^3\) cells) were cultured in 50µl in the presence of IL-7 (10ng/ml) and/or SCF (10ng/ml) in the presence or absence of 1 µM all-trans RA (Sigma-Aldrich) or 1.8 µM RA inhibitor BMS 493 (Tocris, UK) for 3 days or 7 days in the case ILC2p respectively. Cytokine expression in the cell free supernatant was assessed using a bead based cytokine detection assay (FlowCytomix, eBioscience) and was adjusted to the plated density of 5x10\(^3\) cells in 50 µl culture volume.

Retrovirus transduction and adoptive transfer of bone marrow progenitors.
Bone marrow LSK (Lin\(^-\) Sca-1\(^+\) Kit\(^+\), CD45.2) were sorted, cultured with 6 ng/ml IL-3, 5 ng/ml IL-6 and 100 ng/ml SCF and transduced with MSCV-CRE-GFP retrovirus using retronectin (Takara) according to the manufacturer's instructions. After 24h, 2x10\(^5\) cells were injected intravenously into lethally irradiated (950 rads) CD45.1 recipient mice. The recipient mice were treated with 250 µg retinoic acids in 30µl DMSO Intraperitoneally at day 0, day 4 and day 8 post-transplant. Mice were analyzed at 3 weeks post-transplant.

Real time PCR.
Tissues were homogenized using metal beads (Precellys). RNA was extracted using RNAeasy mini kit (Qiagen) and reverse transcribed with Omniscript (Qiagen) according to the manufacturer’s instructions. The cDNA served as template for the amplification of genes of interest and the housekeeping gene (\(b\)-actin) by real-time PCR using SYBR green. Target gene expression was calculated using the comparative method for relative quantification upon
normalisation to \textit{b-actin} gene expression. Primer sequences: (\textit{actb}: 5'-AAGTGTGACGTTGACATCCGTAA-3' and 5'-TGCTGGGCTACATGGGTGTA-3'; \textit{retnlb}: 5'-ATGGGTGTGCTACTGGATGCTT-3' and 5'-AGCAGTGCTGGCAAGTA-3'). For analysis of genes expressed on ILC TaqMan® probes for \textit{RARa}, \textit{RARb}, \textit{RARg} (Life technologies) were used and gene expression was normalized to \textit{hprt1}.

\textit{In Vivo} retinoic acid inhibitor (BMS493) treatment and RA Reconstitution.
A total of 220\,µg of the pan retinoic acid receptor inverse agonist BMS 493 (R&D) resuspended in 30 \,µl of biotechnology performance certified DMSO (Sigma Aldrich) was administered intraperitoneally to \textit{Rag1}−/− mice every day for 8 days as previously described\textsuperscript{18}. Control mice received DMSO only. In some experiments \textit{Rag1}−/− mice were treated with RAi for 5 days followed by infection with \textit{C. rodentium}. Injection of RAi or DMSO continued until the mice were sacrificed but not longer than 14 days of total treatment. In some case mice were simultaneously administered with 400ng of anti-IL-7Ra antibody every 4 days intraperitoneally to block IL-7Ra signaling. A total of 250 \,µg of all-trans-RA (Sigma Aldrich) in 30 \,µl of biotechnology performance certified DMSO (Sigma Aldrich) was administered intraperitoneally to VAI mice every other day for 12 days. Mice not receiving RA received DMSO vehicle.

\textit{Infection with Citrobacter rodentium}.
For \textit{C. rodentium} infections (formerly \textit{Citrobacter freundii}, biotype 4280) strain DBS100 (provided by David Artis, University of Pennsylvania, Philadelphia, Pennsylvania, USA) was prepared by selecting a single colony and culturing in LB broth for 8 hours. Mice pre-treated for 5 days with vehicle control or RAi were inoculated with approximately $1\times10^{10}$ CFU in 200 \,µL of PBS via oral gavage. In some cases VAI mice were treated with 400ng of recombinant mouse IL-22 (rmIL-22, Biolegend) intraperitoneally every day for 4 days starting 2 days before
infection. Treatment with rmIL-22 continued every other day from day 2 after infection until mice were sacrificed.

**Infection with *Trichuris muris***.
Mice were inoculated with 25-30 (low dose) or 150 (high dose) infective *Trichuris muris* eggs on day 0 by oral gavage, and 12-14 days later infected mice were sacrificed and their worm burden was assessed in the cecal epithelial cell layer. C57Bl/6 WT mice were simultaneous treated with vehicle or RAi every day starting upon infections with *T. muris*. In some cases VAI mice were simultaneous treated with 500ng of anti-IL-13 antibody intraperitoneally every 5 days for up to 12 days.

**Goblet cells scoring in the small intestine.**
Sections of the small intestine of control mice or VAI mice were stained with periodic acid-schiff (PAS). 5-10 villi per slide were assessed for PAS positive goblet cells. A total of 2 slides distributed over 3 randomly selected areas were counted. In some cases VAI mice were treated with 500ng of anti-IL-13 antibody intraperitoneally every 5 days for up to two weeks.

**Statistical analysis.**
A two-tailed Student’s t-test was used for all statistical analysis, * p≤ 0.05, **p ≤ 0.005, *** p≤ 0.0005.
Fig. S1.
Reduction of steady state Th17 and Th1 in vitamin A insufficient mice. **A**) Cells isolated from the small intestine lamina propria (SiLP) of control or VAI mice gated on CD4<sup>+</sup> Foxp3<sup>-</sup> T cells and analyzed for GATA3 and ROR<sub>γt</sub> (left panel) and total number of ROR<sub>γt</sub> T cells (Th17) and GATA3<sup>+</sup> T cells (Th2) (right panel). **B**) Flow analysis of SiLP cells stimulated with PMA and ionomicin for 2.5 h, gated on CD4<sup>+</sup> T cells and analyzed for intracellular IL-17A, IL-22 and IFN-γ expression (left panels) and total numbers of IL-17A, IL-22 and IFN-γ producing CD4<sup>+</sup> T cells in the small intestine (right panel). Data represent two independent experiments with 3-5 mice in each experimental group. (Graphs display mean ±SEM).
Fig. S2.
Total numbers and composition of small intestinal ILC in vitamin A insufficient mice. Cells were isolated from the small intestinal lamina propria (SiLP) from control (Ctrl) or vitamin A insufficient (VAI) WT and Rag1⁻/⁻ mice. A) Total numbers of ILC in WT and B) Rag1⁻/⁻ VAI mice. Cells were isolated from the SiLP of WT and VAI mice and C) gated on TCRβ⁻, RORγt⁻ and Gata3⁻ and analyzed for T-bet and Nkp46 expression (left panel) and total numbers of ILC1 (right panel). D) SiLP cells were gated on Thy1.2⁺ and CD4⁺ cells and analyzed for RORγt⁺ TCRβ⁻ LTi_(4) (left panel) and total numbers of LTi_(4). Data represent at least two (A-C) or four (D) independent experiments with 3-5 mice in each experimental group (Graphs mean ±SEM).
Fig. S3. Inverse regulation of ILC subsets by vitamin A in the colon. Cells were isolated from the lamina propria of the colon in WT and VAI mice and analyzed by flow cytometry. RORγt and GATA3 expression in ILC (Lin-, Th1.2+) (left panel) and total numbers of ILC in the large intestine (right panel). Data represent pooled results from two independent experiments with 3-5 mice in each experimental group (Graphs mean ±SEM).
Fig. S4.
Composition of ILC observed in vitamin A insufficient mice. Cells were isolated from the small intestinal lamina propria (SiLP) from WT and VAI mice and analyzed by flow cytometry. 

A) Cells were gated on ILC (Lin−Thy1.2+ cells) and analyzed for the expression of intracellular IL-17A and IL-22 following stimulation with PMA and ionomycin (left panel) and frequencies of IL-17A expressing ILC (right panel). 

B) RORγt expression in ILC3 from Ctrl and VAI Rag1−/− mice. Data represent at least two independent experiments with 3-5 mice in each experimental group (Graphs mean ±SEM)
Fig. S5.

Cytokine expression from ILC in vitamin A deficient mice. Cells were isolated from the small intestinal lamina propria (SiLP) from WT and VAI mice, gated on ILC (Lin−Thy1.2+ cells) and analyzed for the expression of intracellular A) IL-5 and IL-13 cytokine expression following stimulation with PMA and ionomycin (left panel and frequencies of IL-5expressing ILC (right panel). B) Intracellular expression of cytokines in ILC from Ctrl and VAI mice (left panel) and frequencies of cytokine expressing ILC (right panel). Data represent two (A) or one (B) experiment with 3-5 mice in each experimental group. (Graphs mean ±SEM).
**Fig. S6.**

**ILC number and cytokine production in the absence of RA signaling.**

A) Cells were isolated from the small intestinal lamina propria (SiLP) of WT mice (A,B) or Rag1−/− (C,D) treated with retinoic acid receptor inhibitor (RAi) or vehicle control (Veh) for 8 days were stained for GATA3 and RORγt and gated on Lin− and Thy1.2+ cells (right panel) and total numbers of ILC3 (RORγt+) and ILC2 (GATA3+) (right panel)  

B) Flow cytometry of SiLP cells stimulated with PMA and ionomicin for 2h, gated on Lin- Thy1.2+ cells and analyzed for intracellular IL-13 and IL-22 expression (left panel) and total numbers of IL-22 and IL-13 producing ILC in the small intestine (right panel).  

C) Total number of ILC3 and ILC2 isolated from the SiLP of Rag1−/− mice treated with retinoic acid receptor inhibitor (RAi) or vehicle control (Veh) for 8 days  

D) Total numbers of IL-22 and IL-13 producing ILC in the small intestine. Data represent at least two independent experiments with 3-4 mice in each experimental group (Graphs display mean ±SEM).
Fig. S7. Inverse regulation of intestinal ILC subsets by RA signaling occurs independently of the microbiota. Cells were isolated from the small intestine lamina propria (SiLP) of germ free mice treated with retinoic acid receptor inhibitor (RAi) or vehicle control (Veh) for 8 days. GATA3 and RORγt expression in Lin− and Thy1.2+ cells (left panel) and frequencies of ILC3 (RORγt+) and ILC2 (GATA3+) cells (middle panel) and frequencies of Ki67+ ILC (right panel). Data represent two independent experiments with 3-5 mice in each experimental group. (Graphs display mean ±SEM).
Fig. S8. 
Expression of retinoic receptor α (RARα) in ILC2 and ILC3. Cells were isolated from the small intestine lamina propria (SiLP) of WT mice and ILC2 and ILC3 were purified by flow activated cells sorting. A) Relative mRNA expression of Rarα, −β and −γ in ILC2 and B) ILC3. Data represent one experiment with two separate samples in each experimental group.
**Fig. S9. Generation of RARαfl/fl mice.** A targeting vector was generated using BAC clones from the C57BL/6J RPCI-23 BAC library carrying exon 3 of the RARα gene flanked by LoxP sites. In addition the targeting vector contained positive selection markers flanked by FRT sites (Neomycin resistance-NeoR) and F3 (Puromycin resistance-PuroR) inserted into intron 2 and intron 3 respectively (not depicted). The construct was transfected into TaconicArtemis C57BL/6N Tac ES cell line. Correctly targeted ES cells were injected into Balb/c blastocysts to screen for chimerism. Chimeric mice where bred to C57BL/6 females and subsequent to Flp-deleter mice to remove both the Neo and Puro cassette. Expression of the Cre recombinase will allow for specific excision of exon 3 and will generate a frameshift from exon 2 to exon 4 with a premature Stop codon in exon 5 thus resulting in a functional loss of the RARα gene. A similar targeting strategy has been used before (Chapellier B et al. Genesis, 32, p 87-90, 2002). Schematic not drawn to scale.
Fig. S10.
Sorting strategy for isolation of ILC populations and stability in culture in response to RA. A) SiLP cells were stained with lineage markers (NK1.1, TCRβ, TCRγδ, CD11b, CD11c, CD4, CD8a, CD8b, CD19, GR-1, DX5, Ter119) and Thy1.2 and gated on live and CD45+ cells. ILC2 were sorted as Thy1+, Lineage-, KLRG1+ and ILC3 were sorted as Thy1 hyp., KLRG-, and IL-7R+ yielding greater than 99% of cells expressing Gata-3 and Rorgt respectively. B) Post-sort purity measurements indicating greater than 99% purity of sorted populations. C) FACS purified ILC2 (left panel) and ILC3 (right panel) were cultured with vehicle control (Veh), retinoic acid (RA) or retinoic acid signaling inhibitor (RAi) in the presence of IL-7 for 3 days. D) IL-13 (left panel) and IL-22 (right panel) production of ILC2 and ILC3 in the presence of RA or RAi. Data represent two independent experiments. (Graphs display mean ±SEM).
Fig. S11. **Retinoic acid effects ILC3 numbers and promotes IL-22 expression.** A) Sort purified ILC3 cultured with IL-7 and vehicle, RA or RAi were stimulated with IL-1α and IL-1β for 6 hours in the presence of Brefeldin A and assessed for intracellular expression of IL-22. B) IL-22 contents in the culture supernatant of sort purified ILC3 cultured over night with IL-7 and vehicle, RA or RAi and stimulated with IL-1α and IL-1β for 24h. C) ILC3 were purified by fluorescent activated flow sorting (FACS) from small intestinal lamina propria (SiLP) of WT C57Bl/6 mice and cultured with Veh, RA or RAi in the presence of SCF(10ng/ml) for 3 days. RORγt+ expression (left panel) and mean fluorescent intensity of RORγt expression (right panel) and D) total number of live ILC3. Data are representative of at least two independent experiments with 3 experimental groups of cells isolated from 2 mice each (Graph is mean ±SEM).
Fig. S12. RA signaling inhibition augments ILC2 accumulation and IL-13 production. ILC2 were purified by fluorescent activated flow sorting (FACS) from small intestinal lamina propria (SiLP) cells WT mice and cultured with Veh, RA or RAi in the presence of IL-7 (10ng/ml) for 3 days. A) Ki67 expression in ILC2 (left panel) and quantification of frequencies of Ki67+ ILC2. B) Total numbers of GATA3+ ILC2 cultured in the presence of IL-7. C) Cytokine expression in the culture supernatant of cultured ILC2. Data represent two independent experiments with 3 independent groups of ILC2. (Graphs mean ±SEM).
Fig. S13.
**RA supresses IL-13 expression from human ILC2.** PBMC were isolated from healthy donors and ILC (Lin-cKit+IL7R+) were sorted by FACS. Sorted ILC were cultured with RA or RAi in the presence of IL-7 (10ng/ml) and SCF (10ng/ml) for 7 days. IL13 was measured in the cell-free supernatant from cultured ILC adjusted to the plated density of 5x10^3 cells in 50 μl culture volume. Data are representative of 4 independent human donors.
**Fig. S14.**

**Inverse regulation of intestinal ILC subsets by RA occurs independent of IL-25 and TSLP.**

**A)** Cells isolated from the small intestine lamina propria (SilP) of IL-25−/− mice or WT mice treated with retinoic acid receptor inhibitor (RAi) or vehicle control (Veh) for 8 days were stained for GATA3 and RORγt and gated on Lin− and Thy1.2+ cells. **B)** Frequencies of ILC3 (RORγt+) and ILC2 (GATA3+) cells. **C)** RORγt+ and Gata3+ ILC in TSLP−/− mice and **D)** frequencies of ILC3 and ILC2. Data represent one experiment with 2-3 mice in each experimental group. (Graphs display mean ±SEM).
**Fig. S15.**
**IL-33R is dispensable for increased Ki67 expression in ILC2 in the absence of RA signaling.**

**A**) Cells isolated from the small intestine lamina propria (SiLP) of WT mice or IL-33R<sup>−/−</sup> mice and analyzed for Ki67 expression on ILC2. **B**) Frequencies of Ki67<sup>+</sup> ILC2. Data represent two independent experiments with 2-3 mice in each experimental group. (Graphs display mean ±SEM).
RA controls IL-7Rα expression in mouse and human ILC2. ILC2 were purified by fluorescent activated cell sorting from small intestine lamina propria (SiLP) cells and ILC2p from bone marrow cells of WT mice and cultured with Veh, RA or RAi in the presence of IL-7 (10ng/ml) for 3 days (ILC2) or IL-7 and SCF for 7 days (ILC2p). A) IL-7Rα expression on ILC2 after 3 days of culture (left panel) and MFI of IL-7Rα expression (right panel). B) IL-7Rα expression on ILC2p (left panel) and MFI of IL-7Rα expression (right panel). C) PBMC were isolated from different human donors and ILC were sorted by flow cytometry via the expression of ckit and IL-7Rα but the absence of lineage specific markers. IL-7Rα expression on Gata3+ ILC2 after 18 hours of culture with RA or RAi (left panel) and MFI of IL-7Rα normalized to ILC2 cultured with RA (right panel). D) IL-7Rα expression on ILC2 and ILC3 isolated from SiLP of control (Ctrl) or VAI mice (left panel) and MFI of IL-7Rα expression on ILC2 from Ctrl or VAI mice (right panel). E) MFI of IL-7Rα expression on ILC2 isolated from the SiLP of WT mice treated with RAi or vehicle control (Veh) for 8 days. F) MFI of phospho-STAT5 in ILC2 isolated from the SiLP of Ctrl or VAI mice stimulated with IL-7. Data represent at least two independent experiments with 3 experimental groups of sort purified ILC2 or ILC2p (A-B) or three (D-E) or one (F) independent experiments with 3-5 mice in each group or 4 independent human donors (C). (Graphs mean ±SEM)
Fig. S17. **IL-7Rα blockade does not alter ILC2 numbers.** Total number of ILC2 isolated from the small intestine lamina propria (SiLP) of mice treated with either PBS control (Ctrl) or anti α-IL7Rα every 4 days for 8 days. ILC2 were quantified. Results represent one-experiment with 3 mice per group. (Graphs mean ±SEM).
Fig. S18.
Enhanced *Citrobacter rodentium* infection induced pathology and impaired Th17 and ILC3 responses in the absence of vitamin A. **A** Percentile change of original body weight and **B** colon length of vitamin A insufficient (VAI) and control (Ctrl) C57Bl/6 mice infected with *C. rodentium* at Day 9. Large intestinal lamina propria cells were isolated from control (Ctrl) or vitamin A insufficient (VAI) mice 9 days after oral infection with *C. rodentium*. **C** Total amount of ILC3 and IL-22 expressing ILC. **D**) Cells were gated on CD4+ TCRβ⁺Foxp3⁻ cells and analyzed for intracellular RORγt (left panel) and total numbers of Foxp3⁻RORγt⁺ CD4⁺ T cells (Th17) (right panel). **E** IL-17 and IL-22 expression after PMA/Iono stimulation (left panel) and total amount of IL-17 and IL-22⁺ expressing CD4⁺ T cells (right panel). Data represent at least two experiments with 3-5 mice in each experimental group. (Graphs mean ±SEM)
Fig. S19. ILC are the dominant source of IL-13 in VAI RAG1−/− mice. Cells isolated from the small intestine lamina propria (SiLP) from control (Ctrl), vitamin A insufficient (VAI) RAG1−/− mice stimulated with PMA and ionomicin for 2h, gated on CD45+ cells, stained for lineage markers and intracellular IL-13. Data represents three independent experiments.
**Fig. S20.**

**Diminished Th2 response in the absence of RA signaling in response to high dose infection with T. muris.** WT mice treated every other day with retinoic acid receptor inhibitor (RAi) or vehicle control (Veh) for 14 days after oral infection with 150 embryonated eggs of T. muris. **A**) Cells were isolated from the cecal lamina propria of uninfected or infected Veh and RAi treated mice, gated on CD4+ TCRβ+ Foxp3- cells and analyzed for intracellular GATA-3 expression. **B**) Total numbers of GATA-3+ ILC (ILC2) and CD4+ T cell (Th2). **C**) Worm burden in Veh or RAi treated mice 14 days after infection with T. muris. Data representative of three independent experiments with 4-5 mice in each experimental group. (Graphs display mean ±SEM).
Fig. S21. VAI mice show enhanced immunity and ILC2 responses during infection with *T. muris*. WT VAI and control (Ctrl) mice were infected with 30 embryonated *T. muris* eggs. A) Total number of worms in the cecum 13 days after infection. B) Cells were isolated from the lamina propria of the cecum of Ctrl or VAI WT mice 13 days after oral infection with *T. muris*. Cells were gated on Lin- Thy1.2+ cells and analyzed for GATA3 and RORγt or IL-13 and IL-22 expression (left panel) and total number of ILC2 and IL-13+ ILC (right panel). Data represent pooled data from two independent experiments with 3-6 mice in each experimental group. (Graphs display mean ±SEM).
A) ILC and CD4+ T cell gating (small intestinal lamina propria)

[Diagram showing flow cytometry gates for ILC and CD4+ T cell analysis]

B) CLP/ILC2P sorting strategy (Bone marrow)

[Diagram showing flow cytometry gates for CLP/ILC2P sorting]

**Fig. S22.**

**Gating strategy of cell populations**

A) ILC and CD4+ gating strategy for analysis of small intestinal lamina propria (siLP). B) Common lymphoid precursor (CLP) and ILC2 precursor (ILC2P) gating strategy from the bone marrow.
Table S1. mAB clones and suppliers

<table>
<thead>
<tr>
<th>Antigen/Name</th>
<th>Clone</th>
<th>Fluorochrome</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD11b</td>
<td>M1/70</td>
<td>Biotin, Pacific Blue</td>
<td>Biolegend/ebioscience</td>
</tr>
<tr>
<td>CD11c</td>
<td>N418</td>
<td>Biotin/PE-Cy7</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD19</td>
<td>6D5</td>
<td>Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD25</td>
<td>PC61</td>
<td>FITC/PE</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD4</td>
<td>RM4-5</td>
<td>AF700, Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD45</td>
<td>30-F11</td>
<td>APC-Cy7/PErcp-cy5.5</td>
<td>Biolegend/ebioscience</td>
</tr>
<tr>
<td>CD49b</td>
<td>DX5</td>
<td>Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD8b</td>
<td>eBioH35-17.2</td>
<td>Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>GR-1/Ly6G</td>
<td>RB6-8C5</td>
<td>FITC/Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>IL-13</td>
<td>eBio13a</td>
<td>FITC</td>
<td>ebioscience</td>
</tr>
<tr>
<td>IL-4</td>
<td>11B11</td>
<td>PE-Cy7</td>
<td>Biolegend</td>
</tr>
<tr>
<td>IL-5</td>
<td>TRFK5</td>
<td>PE</td>
<td>ebioscience</td>
</tr>
<tr>
<td>IL-9</td>
<td>RM9A4</td>
<td>AF647</td>
<td>Biolegend</td>
</tr>
<tr>
<td>IL-17A</td>
<td>Ebio17B7</td>
<td>BV605/PE/PerCP-Cy5.5</td>
<td>ebioscience</td>
</tr>
<tr>
<td>IL-22</td>
<td>IL22JOP</td>
<td>APC/PerCP-eFluor 710</td>
<td>ebioscience</td>
</tr>
<tr>
<td>GMCSF</td>
<td>MP1-22E9</td>
<td>PE</td>
<td>ebioscience</td>
</tr>
<tr>
<td>IL-10</td>
<td>JES5-16E3</td>
<td>APC</td>
<td>ebioscience</td>
</tr>
<tr>
<td>IL-6</td>
<td>MP5-20F3</td>
<td>PE</td>
<td>ebioscience</td>
</tr>
<tr>
<td>MHCII</td>
<td>M5/114.15.2</td>
<td>AF700</td>
<td>ebioscience</td>
</tr>
<tr>
<td>NK1.1</td>
<td>PK136</td>
<td>Pacific Blue/Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>NKp46</td>
<td>29A1.4</td>
<td>APC</td>
<td>ebioscience</td>
</tr>
<tr>
<td>Sca-1</td>
<td>D7</td>
<td>Pacific Blue/FITC</td>
<td>Biolegend/ebioscience</td>
</tr>
<tr>
<td>Siglec F</td>
<td>E50-2440</td>
<td>PE</td>
<td>BD Biosciences</td>
</tr>
<tr>
<td>IL33R(T1/ST2)</td>
<td>DJ8</td>
<td>Biotin</td>
<td>MDBioproducts</td>
</tr>
<tr>
<td>TCRβ</td>
<td>H57-597</td>
<td>PerCP-Cy5.5/PE-Cy7</td>
<td>ebioscience</td>
</tr>
<tr>
<td>TCRγδ</td>
<td>GL3</td>
<td>Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>Ter-119</td>
<td>Ter119</td>
<td>Biotin</td>
<td>ebioscience</td>
</tr>
<tr>
<td>Thy1.2</td>
<td>30-H12</td>
<td>PE-Cy7/BV605</td>
<td>Biolegend</td>
</tr>
<tr>
<td>GATA3</td>
<td>L50-823</td>
<td>AF488/AF647</td>
<td>BD Biosciences</td>
</tr>
<tr>
<td>RORγt</td>
<td>B2D</td>
<td>PE/PerCP-eFluor 710</td>
<td>ebioscience</td>
</tr>
<tr>
<td>T-bet</td>
<td>Ebio4B10</td>
<td>PE</td>
<td>ebioscience</td>
</tr>
<tr>
<td>Ki67</td>
<td>SolA15</td>
<td>FITC/PE-Cy7</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD127 (IL-7Rα) – Mouse</td>
<td>A7R34</td>
<td>PE-Cy7/APC</td>
<td></td>
</tr>
<tr>
<td>CD45.1</td>
<td>A20</td>
<td>AF700/APC</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD45.2</td>
<td>104</td>
<td>APC/AF780</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD117 (c-Kit)</td>
<td>2B8</td>
<td>PE-Cy7/APC/PErcp-cy5.5</td>
<td>ebioscience</td>
</tr>
<tr>
<td>Phospho-STAT5 (py694)</td>
<td>47/Stat5(pY694)</td>
<td>AF647</td>
<td>BD biosciences</td>
</tr>
<tr>
<td>KLRG1</td>
<td>2F1</td>
<td>PerCP-eFluor 710</td>
<td>ebioscience</td>
</tr>
<tr>
<td>CD127 (IL-7Rα)-Human</td>
<td>eBioRDR5</td>
<td>APC</td>
<td>ebioscience</td>
</tr>
<tr>
<td>Streptavidin</td>
<td></td>
<td>BV421</td>
<td>Biolegend</td>
</tr>
<tr>
<td>CD127 (IL-7Rα) - Mouse</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
References


